期刊文献+

Determination of cefcapene acid by LC-MS and their application to a pharmacokinetic study in healthy Chinese volunteers 被引量:1

Determination of cefcapene acid by LC-MS and their application to a pharmacokinetic study in healthy Chinese volunteers
下载PDF
导出
摘要 Simple,rapid and specific liquid chromatography-mass spectrometry(LC-MS) methods have been developed and validated for the quantification of cefcapene acid in human plasma and urine.Plasma samples were simply pretreated with methanol for deproteinization.Urine samples were briefly diluted with methanol-water(50:50,v/v),and centrifuged to remove large particles.Chromatographic separation was performed on a Hedera ODS-2 column.For the plasma assay,the isocratic mobile phase consisted of 35% solvent A(Methanol) and 65% solvent B(10 mM ammonium acetate buffer solution containing 0.2% folic acid) with a flow rate of 0.3 mL/min.For the urine assay,the isocratic mobile phase consisted of 30% solvent A(Methanol) and 70% solvent B(10 mM ammonium acetate buffer solution containing 0.2% folic acid) with a flow rate of 0.3 mL/min.The assays were linear over the concentration ranges of 0.03-5 μg/mL in plasma and 0.1-400 μg/mL in urine,and were successfully applied to a pharmacokinetic study after single and multiple oral administrations of cefcapene pivoxil hydrochloride tablets in healthy Chinese volunteers. Simple,rapid and specific liquid chromatography-mass spectrometry(LC-MS) methods have been developed and validated for the quantification of cefcapene acid in human plasma and urine.Plasma samples were simply pretreated with methanol for deproteinization.Urine samples were briefly diluted with methanol-water(50:50,v/v),and centrifuged to remove large particles.Chromatographic separation was performed on a Hedera ODS-2 column.For the plasma assay,the isocratic mobile phase consisted of 35% solvent A(Methanol) and 65% solvent B(10 mM ammonium acetate buffer solution containing 0.2% folic acid) with a flow rate of 0.3 mL/min.For the urine assay,the isocratic mobile phase consisted of 30% solvent A(Methanol) and 70% solvent B(10 mM ammonium acetate buffer solution containing 0.2% folic acid) with a flow rate of 0.3 mL/min.The assays were linear over the concentration ranges of 0.03-5 μg/mL in plasma and 0.1-400 μg/mL in urine,and were successfully applied to a pharmacokinetic study after single and multiple oral administrations of cefcapene pivoxil hydrochloride tablets in healthy Chinese volunteers.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2013年第2期84-92,共9页 药物分析学报(英文版)
关键词 Cefcapene acid Cefcapene pivoxil LC-MS Human plasma Urine Pharmacokinetics Cefcapene acid Cefcapene pivoxil LC-MS Human plasma Urine Pharmacokinetics
  • 相关文献

参考文献17

  • 1K. Ishikura, T. Kubota, K. Minami, et al., Synthesis and structure-activity relationships of 7 beta-[(Z)-2-(2-aminothiazol- 4-yl)-3-(substituted)-2-propenoyl-amino]-3- cephems with C-3 substitutions, J. Antibiot. 47 (1994) 466-476.
  • 2A. Saito, New antimicrobial agent series L: cefcapene pivoxil, Jpn. J. Antibiot. 6 (1997) 485-506.
  • 3t-i. Bundgaard, U. Klixbull, Hydrolysis of pivampicillin in buffer and plasma solutions. Formation of a 4-imidazolidinone from ampicillin and formaldehyde, Int. J. Pharm. 27 (1985) 175-183.
  • 4M.-Johansen, H. Bundgaard, E. Falch, Spe'ctrophotometric determination of the rates of hydrolysis of aldehyde releasing prodrugs in aqueous solution and plasma, Int. J. Pharm. 13 (1982) 89-98.
  • 5I. Saiicawa, Y. Nakajima, M. Tai, et al., Studies on beta-lactam antibiotics for medicinal purpose. XXII. Studies on the metabolism of pivaloyloxymethyl (6R,7R)-7-[(Z)-2-(2-amino-thiazol-4-yl)-2-meth- oxy-iminoacetamido]-3-[(5-methyl-2H-tetrazol-2-yl)methyl]-3-cephem- 4-carb-oxylate(T-2588) (2)], Yakugaku Zasshi 106 (1986) 47890.
  • 6K. Totsuka, K. Shimizu, M. Konishi, et al., Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans, Antimicrob. Agents Chemother. 36 (1992) 757-761.
  • 7Y. Toyonaga, T. Ishihara, T. Tezuka, et al., Pharmacokinetic a clinical studies of S-1108 in the pediatric field, Jpn. J. Antibiot. (1993) 991-1002. |.
  • 8R. Fujii, T. Abe, T. Tajima, et al., Pharmacokinetic and clinical studies of S-1108 in the pediatric field. Pediatric Study Group of S-1108, Jpn. J. Antibiot 48 (1995) 921-941.
  • 9M. Fujimoto, Pharmacokinetics of cefcapene pivoxil and AS-924 in gastrectomized patients, Int. J. Antimicrob. Agents 18 (2001) 489-494.
  • 10K. Mizojiri, S. Futaguchi, R. Norikura, et al., Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs, Antimicrob. Agents Chemother. 39 (1995) 1445-1453.

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部